Disease Landscape and Forecast Insights

DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key major depressive disorder patient populations covering 171 countries and…

The highly entrenched generic market for major depressive disorder (MDD) patients poses a challenge for branded agents attempting to gain traction in the United States. The heterogeneous responses…

Numerous drugs from multiple drug classes are used as monotherapies and/or adjunctive therapies for the treatment of major depressive disorder (MDD). The MDD treatment armamentarium is becoming…

In the United States a plethora of pharmacological treatments from an array of drug classes are available to patients with major depressive disorder (MDD), a highly drug-treated condition. Though…

Market Outlook Major depressive disorder (MDD) is a highly drug-treated condition that uses an array of drug classes including, but not limited to, serotonin reuptake inhibitors (SSRIs),…

A subset of major depressive disorder (MDD) patients experience suicidal ideation (SID). Because of the potential lethality of SID, SID in MDD is a highly drug-treated condition that uses an array…

Numerous drugs across multiple drug classes are available for the treatment of MDD. Yet current therapies are not sufficiently effective in all patients, and those patients with TRD have…

MARKET OUTLOOK  MDD is a highly drug-treated condition that utilizes an array of drug classes, including, but not limited to, SSRI , SNRI s, and—as adjunctive therapies—atypical…

For the treatment of major depressive disorder (MDD), which affects more than 17 million people in the United States, there are multiple prescription therapies that are used to treat depressive…

For the first-line treatment of major depressive disorder (MDD), physicians most commonly prescribe a selective serotonin reuptake inhibitor (SSRI), serotonin/norepinephrine reuptake inhibitor (…